Deutsche Märkte geschlossen

Ocean Biomedical, Inc. (OCEA)

NasdaqCM - NasdaqCM Echtzeitpreis. Währung in USD
Zur Watchlist hinzufügen
1,5350-0,2050 (-11,78%)
Börsenschluss: 04:00PM EDT
1,5402 +0,01 (+0,34%)
Nachbörse: 07:45PM EDT

Ocean Biomedical, Inc.

Room 325, 55 Claverick Street
Providence, RI 02903
United States
401 444 7375
https://www.oceanbiomedical.com

Sektor(en)Healthcare
BrancheBiotechnology
Vollzeitmitarbeiter

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Ms. Elizabeth Ng M.B.A.CEO & DirectorN/AN/A1957
Dr. Inderjote Kathuria M.B.A., M.D.Chief Strategy OfficerN/AN/A1967
Dr. Chirinjeev Baboo Kathuria M.B.A., M.D.Founder & Executive Chairman of the BoardN/AN/A1965
Dr. Jack A. Elias M.D.Founder, Chairman of Scientific Advisory Board & Independent DirectorN/AN/A1951
Dr. Jonathan Kurtis M.D., Ph.D.Founder, Chairman of Scientific Advisory Board & DirectorN/AN/A1969
Ms. Jolie G. Kahn CPA, Esq.Chief Financial OfficerN/AN/A1965
Mr. Robert John SweeneyChief Accounting Officer & Assistant SecretaryN/AN/A1965
Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP. The company is based in Providence, Rhode Island. Ocean Biomedical, Inc. operates as a subsidiary of Poseidon Bio, LLC.

Corporate Governance

Ocean Biomedical, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.